Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

Publication ,  Journal Article
Gururangan, S; Fangusaro, J; Young Poussaint, T; Onar-Thomas, A; Gilbertson, RJ; Vajapeyam, S; Gajjar, A; Goldman, S; Friedman, HS; Packer, RJ ...
Published in: Neuro Oncol
November 2012

A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in cases of pediatric recurrent ependymoma (EPN) to estimate sustained objective response rate and progression-free survival (PFS). Eligible patients received 2 doses of single-agent BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ + CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included diffusion-weighted and T1 dynamic contrast enhanced permeability imaging and tumor immunohistochemistry for vascular endothelial growth factor (VEGF)-A and -B, hypoxia inducible factor-2α, VEGF receptor (R)-2, and carbonic anhydrase (CA)-9. Thirteen evaluable patients received a median of 3 courses (range, 2-12) of BVZ + CPT-11. No sustained response was observed in any patient. Median time to progression in 10 patients was 2.2 months (range, 1.9-6.3). Two patients had stable disease for 10 months and 12 months, respectively. Six-month PFS was 25.7% (SE = 11.1%). Grades I-III toxicities related to BVZ treatment included fatigue in 4 patients, systemic hypertension in 2, epistaxis in 1, headache in 1, and avascular necrosis of bone in 1. Although there was a decrease in the mean diffusion ratio following 2 doses of BVZ, it did not correlate with PFS. BVZ + CPT-11 was well tolerated but had minimal efficacy in cases of recurrent EPN.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

November 2012

Volume

14

Issue

11

Start / End Page

1404 / 1412

Location

England

Related Subject Headings

  • Young Adult
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Male
  • Kaplan-Meier Estimate
  • Irinotecan
  • Immunohistochemistry
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gururangan, S., Fangusaro, J., Young Poussaint, T., Onar-Thomas, A., Gilbertson, R. J., Vajapeyam, S., … McLendon, R. (2012). Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol, 14(11), 1404–1412. https://doi.org/10.1093/neuonc/nos213
Gururangan, Sridharan, Jason Fangusaro, Tina Young Poussaint, Arzu Onar-Thomas, Richard J. Gilbertson, Sridhar Vajapeyam, Amar Gajjar, et al. “Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Neuro Oncol 14, no. 11 (November 2012): 1404–12. https://doi.org/10.1093/neuonc/nos213.
Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2012 Nov;14(11):1404–12.
Gururangan, Sridharan, et al. “Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Neuro Oncol, vol. 14, no. 11, Nov. 2012, pp. 1404–12. Pubmed, doi:10.1093/neuonc/nos213.
Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2012 Nov;14(11):1404–1412.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

November 2012

Volume

14

Issue

11

Start / End Page

1404 / 1412

Location

England

Related Subject Headings

  • Young Adult
  • Salvage Therapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Male
  • Kaplan-Meier Estimate
  • Irinotecan
  • Immunohistochemistry
  • Humans
  • Female